ASHEE AMJAD AMJAD WARYAM: Open Payments
NPI 1760920391 · MERCED, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,676 in 144 payments from 11 companies in 2025. Trend: 2023 $1,636 · 2024 $1,965 · 2025 $2,676
Food & beverage: $2,676
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 49 | $919 |
| Janssen Pharmaceuticals, Inc | 28 | $486 |
| Otsuka America Pharmaceutical, Inc. | 31 | $450 |
| Teva Pharmaceuticals USA, Inc. | 17 | $292 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $262 |
| Lundbeck LLC | 4 | $78 |
| Neurocrine BioSciences, Inc. | 3 | $66 |
| Alkermes, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Almatica Pharma LLC | 1 | $18 |
Products named: VRAYLAR, REXULTI, INVEGA SUSTENNA, AUSTEDO XR, CAPLYTA, ABILIFY ASIMTUFII, SPRAVATO, INGREZZA.
Industry payments across CA — which companies pay providers there.
